RU2001129362A - COMPOSITION INCLUDING UNDECANOATE TESTOSTERONE AND CASTOR BUTTER - Google Patents

COMPOSITION INCLUDING UNDECANOATE TESTOSTERONE AND CASTOR BUTTER

Info

Publication number
RU2001129362A
RU2001129362A RU2001129362/14A RU2001129362A RU2001129362A RU 2001129362 A RU2001129362 A RU 2001129362A RU 2001129362/14 A RU2001129362/14 A RU 2001129362/14A RU 2001129362 A RU2001129362 A RU 2001129362A RU 2001129362 A RU2001129362 A RU 2001129362A
Authority
RU
Russia
Prior art keywords
liquid carrier
testosterone undecanoate
pharmaceutical composition
dissolved
castor oil
Prior art date
Application number
RU2001129362/14A
Other languages
Russian (ru)
Other versions
RU2246296C2 (en
Inventor
ДЕ Хенрик НЕЙС
Сьюзн ЧАНДЛЕР
Элизабет Энн ПЕРРИ
Джозефин Джоан Кристин ФЕРДИНАНДО
Original Assignee
Акцо Нобель Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Акцо Нобель Н.В. filed Critical Акцо Нобель Н.В.
Publication of RU2001129362A publication Critical patent/RU2001129362A/en
Application granted granted Critical
Publication of RU2246296C2 publication Critical patent/RU2246296C2/en

Links

Claims (8)

1. Фармацевтическая композиция в виде капсулы для перорального введения, включающая ундеканоат тестостерона в качестве активного ингредиента, растворенный в фармацевтически приемлемом жидком носителе, отличающаяся тем, что жидкий носитель включает, по меньшей мере, 50 мас.% касторового масла.1. A pharmaceutical composition in the form of a capsule for oral administration, comprising testosterone undecanoate as an active ingredient, dissolved in a pharmaceutically acceptable liquid carrier, characterized in that the liquid carrier comprises at least 50 wt.% Castor oil. 2. Фармацевтическая композиция по п.1, отличающаяся тем, что единственный жидкий носитель представляет собой касторовое масло.2. The pharmaceutical composition according to claim 1, characterized in that the sole liquid carrier is castor oil. 3. Фармацевтическая композиция по п.1, отличающаяся тем, что жидкий носитель дополнительно включает 30 - 50 мас.% липофильного поверхностно-активного вещества, имеющего значение ГЛБ ниже 10.3. The pharmaceutical composition according to claim 1, characterized in that the liquid carrier further comprises 30 to 50 wt.% Lipophilic surfactant having an HLB value below 10. 4. Фармацевтическая композиция по п.3, отличающаяся тем, что липофильное поверхностно-активное вещество представляет собой лаурогликоль.4. The pharmaceutical composition according to claim 3, characterized in that the lipophilic surfactant is lauroglycol. 5. Фармацевтическая композиция по любому из предшествующих пунктов, отличающаяся тем, что ундеканоат тестостерона растворяют с концентрацией 200-250 мг/мл.5. The pharmaceutical composition according to any one of the preceding paragraphs, characterized in that the testosterone undecanoate is dissolved at a concentration of 200-250 mg / ml. 6. Применение ундеканоата тестостерона для приготовления лекарственного препарата в форме раствора для перорального введения, где ундеканоат тестостерона растворяют в фармацевтически приемлемом жидком носителе, отличающееся тем, что жидкий носитель включает, по меньшей мере, 50 мас.% касторового масла.6. The use of testosterone undecanoate for the preparation of a medicament in the form of an oral solution, wherein testosterone undecanoate is dissolved in a pharmaceutically acceptable liquid carrier, characterized in that the liquid carrier comprises at least 50% by weight of castor oil. 7. Способ лечения, включающий введение ундеканоата тестостерона мужчине при необходимости доставки андрогена, отличающийся тем, что ундеканоат тестостерона вводят перорально в форме раствора в носителе, причем последний включает, по меньшей мере, 50 мас.% касторового масла.7. A method of treatment, comprising administering testosterone undecanoate to a man if it is necessary to deliver androgen, characterized in that the testosterone undecanoate is administered orally in the form of a solution in the carrier, the latter comprising at least 50 wt.% Castor oil. 8. Фармацевтическая композиция в виде капсулы для перорального введения, включающая ундеканоат тестостерона в качестве активного ингредиента, растворенный в фармацевтически приемлемом жидком носителе с концентрацией 200-250 мг/мл.8. A pharmaceutical composition in the form of a capsule for oral administration, comprising testosterone undecanoate as an active ingredient, dissolved in a pharmaceutically acceptable liquid carrier with a concentration of 200-250 mg / ml.
RU2001129362/15A 1999-04-01 2000-03-27 Composition comprising testosterone undecanoate and castor oil RU2246296C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99302581 1999-04-01
EP99302581.6 1999-04-01

Publications (2)

Publication Number Publication Date
RU2001129362A true RU2001129362A (en) 2003-08-27
RU2246296C2 RU2246296C2 (en) 2005-02-20

Family

ID=8241306

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001129362/15A RU2246296C2 (en) 1999-04-01 2000-03-27 Composition comprising testosterone undecanoate and castor oil

Country Status (27)

Country Link
EP (1) EP1189620B1 (en)
JP (1) JP2002541111A (en)
KR (1) KR100666016B1 (en)
CN (1) CN1155385C (en)
AT (1) ATE269708T1 (en)
AU (1) AU768537B2 (en)
BR (1) BR0009465A (en)
CA (1) CA2366856C (en)
CZ (1) CZ298573B6 (en)
DE (1) DE60011771T2 (en)
DK (1) DK1189620T3 (en)
ES (1) ES2222199T3 (en)
HK (1) HK1043544A1 (en)
HU (1) HU229455B1 (en)
ID (1) ID30481A (en)
IL (2) IL145524A0 (en)
MX (1) MXPA01009919A (en)
NO (1) NO329420B1 (en)
NZ (1) NZ514290A (en)
PL (1) PL195163B1 (en)
PT (1) PT1189620E (en)
RU (1) RU2246296C2 (en)
SK (1) SK286071B6 (en)
TR (1) TR200102769T2 (en)
TW (1) TWI280124B (en)
WO (1) WO2000059512A1 (en)
ZA (1) ZA200107781B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6652880B1 (en) 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
GB9907715D0 (en) * 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
JO2505B1 (en) * 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت method and pharmaceutical compositions for reliable achievements of acceptable serum testosterone levels
DK1530965T3 (en) * 2003-11-11 2006-07-17 Mattern Udo Controlled release delivery system for nasal application
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
US20060140820A1 (en) 2004-12-28 2006-06-29 Udo Mattern Use of a container of an inorganic additive containing plastic material
KR20080009201A (en) 2005-04-15 2008-01-25 클라루스 쎄러퓨틱스, 아이엔씨. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
CN101600417B (en) 2006-10-04 2012-05-30 M&P专利股份公司 Controlled release delivery system for nasal application of neurotransmitters
GB0818473D0 (en) 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
US11304960B2 (en) * 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
ES2525520T3 (en) * 2010-04-12 2014-12-26 Clarus Therapeutics, Inc. Oral testosterone ester formulations and methods to treat testosterone deficiency with them
GB201006200D0 (en) * 2010-04-14 2010-06-02 Ayanda As Composition
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
UA114705C2 (en) * 2011-01-26 2017-07-25 Аллерган, Інк. Androgen composition for treating an opthalmic condition
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
WO2015193224A1 (en) 2014-06-17 2015-12-23 Merck Sharp & Dohme B.V. Stable formulations of testosterone undecanoate
JP6723166B2 (en) * 2014-06-19 2020-07-15 ソルラル ファーマ エーピーエス Solid oral dosage form of lipophilic compound
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
RU2017111503A (en) * 2014-08-29 2018-10-05 Липосин Инк. COMPOSITIONS (17-β) -3-OXOANDROST-4-EN-17-IL UNDECANOATE AND METHODS FOR PRODUCING AND USING THEM
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1102095A (en) * 1993-10-30 1995-05-03 浙江医科大学 Long-acting androgen preparation-undecylic acid testis injection
GB9608719D0 (en) * 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
SE9700642D0 (en) * 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Means and ways of preventing and treating the metabolic syndrome

Similar Documents

Publication Publication Date Title
RU2001129362A (en) COMPOSITION INCLUDING UNDECANOATE TESTOSTERONE AND CASTOR BUTTER
ATE269708T1 (en) FORMULATION CONTAINING TESTOSTEONUNDECANOATE AND CASCIN OIL
DK2600851T3 (en) PHARMACEUTICAL DOSAGE FORM CONTAINING 6'-FLUORO- (N-METHYL OR N, N-DIMETHYL -) - 4-PHENYL-4 ', 9'-DIHYDRO-3'H-SPIRO [CYCLOHEXAN-1,1'-PYRANO [3,4, B] INDOL] -4-AMINE FOR TREATMENT OF NEUROPATHIC PAIN
AU2006324219B2 (en) Butylphthalide intravenous emulsion and application thereof
US20040110828A1 (en) Tetrahydrocannabinol compositions and methods of manufacture and use thereof
CA2185347A1 (en) A carrier for hydrophobic drugs and a pharmaceutical composition based thereon
JP2010235636A (en) Pharmaceutical formulation of taxanes
JP5052558B2 (en) Gel ointment
GB9907715D0 (en) Pharmaceutical compositions
BRPI0008228B1 (en) pharmaceutical composition containing n-benzoyl staurosporine and solubilizing agents
AU703842B2 (en) Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and methods for treatment of metabolic and cardiovascular disorders
NZ539046A (en) Chemotherapeutic self-emulsifying microemulsion compositions of paclitaxel with improved oral bioavailability
CA1249223A (en) Solid drug formulations and stable suspensions
JP5435659B2 (en) Formulation form for oral mucosal administration of triptan
RU2216342C2 (en) Cyclosporin solution
JP2006509785A (en) Oral microemulsion composition of biphenyldimethyldicarboxylic acid
WO2007147371A2 (en) Pharmaceutical composition for oral administration
JPH044300B2 (en)
US20230089681A1 (en) Use of a combination of sulficant compounds with a liquid carrier as a self emulsifying drug delivery system
AU745008B2 (en) Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors
JP3748912B2 (en) High concentration solution formulation of aureobasidins
US20060024341A1 (en) Microemulsion composition and related method
KR20050030282A (en) Formulation and manufacturing process solubilized simvastatin soft capsules
RU2642244C2 (en) Oral pharmaceutical compositions of testosterone esters and method for testosterone shortage treatment with their use
RU95119385A (en) PHARMACEUTICAL COMPOSITION CONTAINING LIPOPHILIC MEDICINES